← Back to list
08.02.42, Penpulimab-kcqx
Act
by Dec 29, 2025
Effective date
Dec 29, 2025
Identified
Jun 19, 2026
Summary
Independence Blue Cross published version 08.02.42b of their Penpulimab-kcqx coverage policy, effective 12/29/2025, establishing medical necessity criteria for this immunotherapy drug across anal carcinoma, appendiceal cancers, and head and neck cancers (nasopharyngeal carcinoma). The policy specifies coverage conditions including required genetic markers, prior treatment history, disease stage, and performance status thresholds. Billing teams must understand these criteria to support prior authorization requests and ensure claims meet coverage requirements.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.
Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.
What to do
by Dec 29, 2025 · 10 steps
01Billing team and prior authorization staff must update systems to reflect IBX policy 08.02.42b for penpulimab-kcqx coverage.
02Remove old version 08.02.42 from all reference materials and billing software.
03For any penpulimab-kcqx claims submitted after this date.
04Verify diagnosis matches covered indications (anal carcinoma, appendiceal cancer, nasopharyngeal carcinoma).
05Confirm all medical necessity criteria are met, including required genetic testing results (dMMR/MSI-H or POLE/POLD1 mutations for appendiceal; metastatic disease staging for anal/NPC).
06Document prior immunotherapy history and ECOG performance status in prior authorization requests.
07Use HCPCS codes C9399 or J3590 for billing.
08Route all penpulimab-kcqx requests through prior authorization process with clinical documentation supporting criteria.
09Claims submitted without proper documentation of medical necessity will be denied.
10Update encounter templates and provider communications to include reminders about required documentation.
Codes mentioned
C9399J3590C11.0C11.1C11.2C11.3C11.8C11.9C14.0C14.2C17.0C17.1C17.2C17.3
Original notice
08.02.42, Penpulimab-kcqx
medpolicy.ibx.com · Always check the source before changing claims.
Related changes
See all Independence Blue Cross changes →08.02.42b, Penpulimab-kcqxLowEffective Oct 1, 2026 · PharmacyMA08.186, Penpulimab-kcqxMediumEffective Dec 29, 2025 · PharmacyMA08.186a, Penpulimab-kcqxMediumEffective Jun 1, 2026 · PharmacyMA08.173b, Tislelizumab-jsgr (Tevimbra®)MediumEffective Oct 1, 2026 · PharmacyBrowse every Independence Blue Cross change in the policy list